Literature DB >> 3529325

Methods for evaluating the penetration of beta-lactam antibiotics into tissues.

R Wise.   

Abstract

Methods for the study of tissue penetration by beta-lactam antibiotics have been critiqued and compared. Mathematical models may be useful in assessments of the influence of lipid solubility and protein binding on tissue penetration. In vitro models may be used for evaluation of the probable pharmacokinetic properties of beta-lactams but are of greater use in studies of the interaction between antimicrobial concentrations and the kinetics of bacterial killing. Numerous animal models have been used. Fibrin clots, intraperitoneal cages, and soft tissue models all tend to yield limited information on tissue penetration as they often have no pathophysiologic counterpart in humans. Three types of studies in humans--tissue homogenates, body fluids, and experimental fluids--all entail certain advantages and problems. Tissue homogenates are often contaminated with body fluids, such as urine and bile. The usefulness of drug assays in ascitic or pleural fluid is limited by the depot effect. Studies of experimental fluids (e.g., fluid from blisters induced chemically or by suction) may have some clinical relevance and yield consistent results.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3529325     DOI: 10.1093/clinids/8.supplement_3.s325

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  11 in total

1.  Tissue penetration by ertapenem, a parenteral carbapenem administered once daily, in suction-induced skin blister fluid in healthy young volunteers.

Authors:  T Laethem; I De Lepeleire; J McCrea; J Zhang; A Majumdar; D Musson; D Rogers; S Li; M Guillaume; A Parneix-Spake; P Deutsch
Journal:  Antimicrob Agents Chemother       Date:  2003-04       Impact factor: 5.191

Review 2.  Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: distribution in tissue.

Authors:  Markus Müller; Amparo dela Peña; Hartmut Derendorf
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

3.  Quantification of tissue distribution of antibiotics by kinetic hysteresis analysis.

Authors:  U Ganzinger; K Neumann
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

4.  Pharmacokinetics of cefpodoxime in plasma and skin blister fluid following oral dosing of cefpodoxime proxetil.

Authors:  M T Borin; G S Hughes; C R Spillers; R K Patel
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

Review 5.  The clinical evaluation of antibacterial drugs: guidelines of the British Society for Antimicrobial Chemotherapy.

Authors:  R G Finch
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-07       Impact factor: 3.267

6.  Pharmacokinetics of cefetamet in plasma and skin blister fluid.

Authors:  W Zimmerli; S Sansano; B Wittke
Journal:  Antimicrob Agents Chemother       Date:  1996-01       Impact factor: 5.191

Review 7.  Considerations in dosage selection for third generation cephalosporins.

Authors:  J H Yuk-Choi; C H Nightingale; T W Williams
Journal:  Clin Pharmacokinet       Date:  1992-02       Impact factor: 6.447

8.  Pharmacokinetics of sparfloxacin in the serum and vitreous humor of rabbits: physicochemical properties that regulate penetration of quinolone antimicrobials.

Authors:  W Liu; Q F Liu; R Perkins; G Drusano; A Louie; A Madu; U Mian; M Mayers; M H Miller
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

9.  Pharmacodynamic activity of a cephalosporin, Ro 40-6890, in human skin blister fluid: antibiotic activity in concert with host defense mechanisms.

Authors:  J F Hoogkamer; W H Hesse; S Sansano; W Zimmerli
Journal:  Antimicrob Agents Chemother       Date:  1993-12       Impact factor: 5.191

10.  Peak blistering point: influence on fluid levels of 5-MOP in human skin in vivo after systemic administration.

Authors:  P Humbert; P Treffel; S Makki; J Millet; P Agache
Journal:  Arch Dermatol Res       Date:  1991       Impact factor: 3.017

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.